MX343271B - Procesos de cultivo celular. - Google Patents

Procesos de cultivo celular.

Info

Publication number
MX343271B
MX343271B MX2014003366A MX2014003366A MX343271B MX 343271 B MX343271 B MX 343271B MX 2014003366 A MX2014003366 A MX 2014003366A MX 2014003366 A MX2014003366 A MX 2014003366A MX 343271 B MX343271 B MX 343271B
Authority
MX
Mexico
Prior art keywords
cell culture
culture processes
urin
adamts
cho
Prior art date
Application number
MX2014003366A
Other languages
English (en)
Inventor
Giovagnoli Andre
Roy Sylvain
Ducros Veronique
Charlot Virginie
Stauffer Yves-Olivier
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX343271B publication Critical patent/MX343271B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para cultivar células de mamífero que secretan proteína heteróloga en un sobrenadante de cultivo celular en el cual el sobrenadante de cultivo celular tiene una concentración de CO2 disuelto de 1 a 10%, en donde el cultivo celular es un cultivo celular continuo manteniendo a una densidad desde 1.4x106 hasta 2.8 x 106 células/ml, en donde la proteína heteróloga es el Factor VIII.
MX2014003366A 2007-12-27 2008-12-22 Procesos de cultivo celular. MX343271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US932807P 2007-12-27 2007-12-27
PCT/US2008/088036 WO2009086309A2 (en) 2007-12-27 2008-12-22 Cell culture processes

Publications (1)

Publication Number Publication Date
MX343271B true MX343271B (es) 2016-10-31

Family

ID=40350258

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015014311A MX343269B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.
MX2014003366A MX343271B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015014311A MX343269B (es) 2007-12-27 2008-12-22 Procesos de cultivo celular.

Country Status (21)

Country Link
US (2) US9359629B2 (es)
EP (4) EP2574676B1 (es)
JP (3) JP5727790B2 (es)
KR (4) KR20180005287A (es)
CN (2) CN106222220A (es)
AR (2) AR069956A1 (es)
AU (1) AU2008345231B2 (es)
BR (1) BR122019022434B8 (es)
CA (1) CA2709890A1 (es)
DK (3) DK2574677T3 (es)
ES (3) ES2649094T3 (es)
HK (1) HK1246827A1 (es)
HR (3) HRP20171375T1 (es)
HU (2) HUE036496T2 (es)
MX (2) MX343269B (es)
NZ (1) NZ586250A (es)
PL (3) PL2235197T3 (es)
PT (3) PT2574677T (es)
SG (2) SG187397A1 (es)
SI (3) SI2235197T1 (es)
WO (1) WO2009086309A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716762A2 (pt) 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP4269578B8 (en) 2008-03-06 2024-07-17 Halozyme, Inc. Soluble hyaluronidase composition
TWI610936B (zh) 2008-10-20 2018-01-11 艾伯維有限公司 使用蛋白質ａ親和性層析進行抗體之分離及純化
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
US8580554B2 (en) * 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8313926B2 (en) * 2009-07-31 2012-11-20 Baxter International Inc. Methods for expressing ADAMTS proteins in cell culture medium supplemented with zinc
PL3626736T3 (pl) * 2010-07-08 2025-10-13 Takeda Pharmaceutical Company Limited Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
WO2012122611A1 (en) * 2011-03-11 2012-09-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SG11201607929PA (en) 2014-03-25 2016-10-28 Genentech Inc Methods of preparing a poloxamer for use in cell culture medium
MX2016013223A (es) * 2014-04-10 2017-04-27 Bayer Healthcare Llc Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular.
CN106536746A (zh) * 2014-06-03 2017-03-22 鲁宾有限公司 用于生产蛋白的细胞培养方法
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
JP7213180B2 (ja) * 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
CN114657118B (zh) * 2021-12-31 2023-12-01 广州齐志生物工程设备有限公司 一种2bs细胞在生物反应器内的多倍放大方法
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN116064409A (zh) * 2023-01-06 2023-05-05 四川阿思科力生物科技有限公司 一种大规模高产量细胞连续培养和收获的生产工艺
EP4702164A1 (en) 2023-04-24 2026-03-04 Quantitative Biosciences, Inc. Engineered biosensor strains of e. coli for continuous aerobic detection of analytes
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
EP4711442A1 (en) 2024-09-15 2026-03-18 Quantitative Biosciences, Inc. Microfluidic chip for the parallel culture of microbial biosensor strains

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4921792A (en) * 1987-11-27 1990-05-01 Miles Inc. Continuous cell dispersion, cultivation and substance recovery process
JPH0787799B2 (ja) * 1988-03-30 1995-09-27 森永製菓株式会社 モノクローナル抗体生産増強法
US6100050A (en) 1989-08-17 2000-08-08 Dade Behring Ag Factor VIII:Ca chromogenic assay
NL9000917A (nl) 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JP3459416B2 (ja) 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
WO1997021824A2 (en) * 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
WO1998000521A1 (fr) * 1996-06-28 1998-01-08 The Green Cross Corporation Milieux exempts de serum, methode de culture de cellules d'origine animale, et procede de production de substances physiologiquement actives
US5854021A (en) 1997-02-28 1998-12-29 Bayer Corporation Enhance protein production method
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
JP4674021B2 (ja) 1999-07-13 2011-04-20 ビオヴィトルム・アクチボラゲット（プブリクト） 安定第ｖｉｉｉ因子組成物
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
SE518174C2 (sv) 1999-11-16 2002-09-03 Appliedsensor Sweden Ab Detektionsförfarande av oönskad mikrobiell infektion i animaliecellodling
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
JP2003047461A (ja) * 2001-07-31 2003-02-18 Astec:Kk アパタイトシ−トを用いた細胞の高密度細胞培養法及び培養装置、細胞培養モジュール
KR100909316B1 (ko) * 2001-08-31 2009-07-24 바이엘 헬스케어 아게 고세포밀도 발효를 수행하기 위한 유닛 및 방법
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
HUP0402158A2 (hu) * 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US20030119723A1 (en) 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2005532057A (ja) * 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
WO2004092218A1 (ja) * 2003-04-17 2004-10-28 Mitsubishi Pharma Corporation 組換えアンチトロンビンの製造方法
CN104388324A (zh) * 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US8530192B2 (en) * 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
CA2633306A1 (en) * 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
AU2008253230B2 (en) 2007-05-22 2013-07-18 Takeda Pharmaceutical Company Limited Preparative purification process for human furin

Also Published As

Publication number Publication date
SG187397A1 (en) 2013-02-28
HK1246827A1 (en) 2018-09-14
ES2649094T3 (es) 2018-01-10
CA2709890A1 (en) 2009-07-09
HUE036712T2 (hu) 2018-07-30
JP5727790B2 (ja) 2015-06-03
HUE036496T2 (hu) 2018-07-30
CN101910408A (zh) 2010-12-08
DK2574677T3 (da) 2017-11-06
WO2009086309A3 (en) 2009-10-01
KR20160112025A (ko) 2016-09-27
PT2235197T (pt) 2017-10-11
PT2574676T (pt) 2017-10-11
KR20100097752A (ko) 2010-09-03
EP2574676B1 (en) 2017-08-30
US20160244506A1 (en) 2016-08-25
KR101798813B1 (ko) 2017-11-16
SG10201503304RA (en) 2015-06-29
PL2235197T3 (pl) 2018-01-31
EP2574677A1 (en) 2013-04-03
JP2016013140A (ja) 2016-01-28
EP3255152A1 (en) 2017-12-13
EP2574677B1 (en) 2017-09-13
DK2574676T3 (en) 2017-10-09
AR069956A1 (es) 2010-03-03
SI2574677T1 (sl) 2017-11-30
KR20180005287A (ko) 2018-01-15
US9359629B2 (en) 2016-06-07
JP5890854B2 (ja) 2016-03-22
SI2574676T1 (sl) 2017-10-30
EP2235197A2 (en) 2010-10-06
KR20170126514A (ko) 2017-11-17
AU2008345231A1 (en) 2009-07-09
JP2014100148A (ja) 2014-06-05
AU2008345231B2 (en) 2014-09-11
PT2574677T (pt) 2017-10-19
KR101818411B1 (ko) 2018-01-12
ES2644089T3 (es) 2017-11-27
CN106222220A (zh) 2016-12-14
ES2647294T3 (es) 2017-12-20
JP2011507551A (ja) 2011-03-10
NZ586250A (en) 2012-11-30
PL2574677T3 (pl) 2017-12-29
US20090176269A1 (en) 2009-07-09
PL2574676T3 (pl) 2017-12-29
EP2235197B1 (en) 2017-07-26
BR122019022434B1 (pt) 2020-11-03
HRP20171495T1 (hr) 2018-01-26
SI2235197T1 (sl) 2017-10-30
HRP20171375T1 (hr) 2017-12-15
DK2235197T3 (en) 2017-10-09
BRPI0821481A2 (pt) 2014-11-04
WO2009086309A2 (en) 2009-07-09
AR110864A2 (es) 2019-05-08
KR101659458B1 (ko) 2016-09-23
HRP20171374T1 (hr) 2017-12-29
MX343269B (es) 2016-10-31
EP2574676A1 (en) 2013-04-03
BR122019022434B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
MX343269B (es) Procesos de cultivo celular.
GB2446525A (en) Stem cell culture medium and method
MX2009010154A (es) Materiales y metodos para la produccion eficiente de succinato y malato.
EP2275531A4 (en) METHOD FOR IMPROVING A PLURIPOTENTIAL STEM CELL
CL2011001926A1 (es) Biorreactor para el cultivo de celulas de mamiferos donde dicho biorreactor posee un volumen de al menos 4000 l y al menos un impulsor superior y al menos un impulsor de fondo, donde el impulsor superior es un impulsor de hidroplano; metodo de cultivo; sistema de bioreactor.
TW200736399A (en) Expansion and differentiation of neural stem cells under low oxygen conditions
MX2009011805A (es) Mejora de las concentraciones de polipeptido del factor viii en cultivos celulares.
CR20120560A (es) PRODUCCIÓN DE TNFR-Ig Y FUSIÓN DE PROTEÍNA
CL2008001156A1 (es) Metodo para producir una proteina de fusion tnfr en un cultivo celular que comprende cultivar celulas de mamifero que contienen un gen que codifica la proteina de fusion en un medio de cultivo de celulas que comprende un compuesto anti-envejecimiento.
SG169359A1 (en) A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
MX2007007040A (es) Proceso para el control de produccion de productos quimicos finos.
WO2008135498A3 (en) Prevention of protein degradation in mammalian cell cultures
IL190322A0 (en) Nutrient medium for the cultivation of a cell culture
DK1623023T3 (da) Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
DK1720979T3 (da) Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
GB0702261D0 (en) No title
WO2003010304A3 (de) Verfahren zur herstellung isolierter zellkulturen, kulturmedium zur kultivierung von zellkulturen und zellkultur
DK1495112T3 (da) Cellekulturmedium
TW200636068A (en) A method of culturing a cell and use of the same
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
MX2011009023A (es) Metodos para seleccionar celulas eucarioticas que expresan una proteina heterologa.
MX2010005079A (es) Metodos para medir la viabilidad celular sin usar celulas de control.
MX2010001996A (es) Vehiculo para celulas que contienen colageno.
MX2007005210A (es) Medio de cultivo de celula libre de suero para las celulas de los mamiferos.